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OBJECTIVE—Insulin resistance is associated with elevated
content of skeletal muscle lipids, including triacylglycerols (TAGs)
and diacylglycerols (DAGs). DAGs are by-products of lipolysis
consecutive to TAG hydrolysis by adipose triglyceride lipase
(ATGL) and are subsequently hydrolyzed by hormone-sensitive
lipase (HSL). We hypothesized that an imbalance of ATGL relative
to HSL (expression or activity) may contribute to DAG accumu-
lation and insulin resistance.
RESEARCH DESIGN AND METHODS—We ﬁrst measured
lipase expression in vastus lateralis biopsies of young lean (n=9),
young obese (n=9), and obese-matched type 2 diabetic (n=8)
subjects. We next investigated in vitro in human primary myotubes
the impact of altered lipase expression/activity on lipid content and
insulin signaling.
RESULTS—Muscle ATGL protein was negatively associated
with whole-body insulin sensitivity in our population (r = 20.55,
P = 0.005), whereas muscle HSL protein was reduced in obese
subjects. We next showed that adenovirus-mediated ATGL over-
expression in human primary myotubes induced DAG and ceramide
accumulation. ATGL overexpression reduced insulin-stimulated
glycogen synthesis (230%, P , 0.05) and disrupted insulin sig-
naling at Ser1101 of the insulin receptor substrate-1 and down-
stream Akt activation at Ser473. These defects were fully
rescued by nonselective protein kinase C inhibition or concom-
itant HSL overexpression to restore a proper lipolytic balance.
We show that selective HSL inhibition induces DAG accumula-
tion and insulin resistance.
CONCLUSIONS—Altogether, the data indicate that altered
ATGL and HSL expression in skeletal muscle could promote
DAG accumulation and disrupt insulin signaling and action.
Targeting skeletal muscle lipases may constitute an interesting
strategy to improve insulin sensitivity in obesity and type 2
diabetes. Diabetes 60:1734–1742, 2011
S
keletal muscle insulin resistance is a strong risk
factor of type 2 diabetes and cardiovascular dis-
eases (1,2). Dysfunctional adipose tissue can lead
to lipid oversupply and increased ﬂux of free fatty
acids (FFAs) into skeletal muscle and is associated with the
accumulation of intramyocellular triacylglycerols (IMTGs)
(3–5). This chronic lipid overload in tissues can evolve to
a state of lipotoxicity leading to cell dysfunction (6). The
term “lipotoxicity” deﬁnes more generally in skeletal muscle
a state of lipid overload (increased concentrations of long-
chain acyl-CoA, diacylglycerols [DAGs], and ceramide)
causing insulin resistance (7–12). DAGs have been shown
to activate novel protein kinase C (PKC) isoforms, such as
the novel PKCu leading to insulin receptor substrate-1
(IRS-1) serine phosphorylation and impaired downstream
insulin signaling (10–13). DAGs can be formed through
multiple pathways but are also formed as intermediates
during triacylglycerol (TAG) synthesis and hydrolysis (14).
The control of lipolysis in skeletal muscle has mainly been
attributed to hormone-sensitive lipase (HSL), which ex-
hibits a 10-fold higher speciﬁc activity for DAG than TAG
(15). HSL null mice display normal TAG hydrolase activity
after an overnight fast and accumulate large amounts of
DAG (16). Recently it was shown that adipose triglyceride
lipase (ATGL) plays a major role in the regulation of cel-
lular TAG stores in various tissues of the body, including
heart and skeletal muscle (17,18). ATGL speciﬁcally drives
the hydrolysis of TAG into DAG (18). ATGL-deﬁcient mice
are more insulin sensitive and glucose tolerant despite a
threefold increase in TAG content in their skeletal muscle
(17). The molecular mechanism underlying this phenotype
remains unclear. In the current study, we hypothesized
that an imbalance of ATGL relative to HSL could increase
intracellular DAG concentrations and promote insulin re-
sistance. To test this hypothesis, we ﬁrst examined the
relationship between muscle ATGL expression and whole-
body insulin sensitivity in a wide range of subjects. We
next manipulated the expression/activity of ATGL and HSL
in vitro in cultured human primary skeletal muscle cells and
evaluated its impact on lipid pools and insulin signaling.
RESEARCH DESIGN AND METHODS
Skeletal muscle cell culture. Satellite cells from vastus lateralis or rectus
abdominis biopsies of lean, healthy, insulin-sensitive subjects were isolated
by trypsin digestion, preplated on an uncoated petri dish for 1 h to remove
ﬁbroblasts, and subsequently transferred to T-25 collagen-coated ﬂasks in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) low glucose (1 g/L) supple-
mented with 10% FBS and growth factors (human epidermal growth factor,
BSA, dexamethasone, gentamicin, amphotericin B [Fungizone, Invitrogen,
Grand Island, NY], and fetuin) as previously described (19). Cells from several
donors were pooled and grown at 37°C in a humidiﬁed atmosphere of 5% CO2.
Differentiation of myoblasts into myotubes was initiated at approximately 90%
conﬂuence by switching to a-minimum essential medium with antibiotics,
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ORIGINAL ARTICLE2% FBS, and fetuin. The medium was changed every other day, and cells were
grown up to 5–6 days.
Overexpression of lipases. Human ATGL and HSL cDNAs were cloned into
the pcDNA3 vector (Invitrogen Corp., Carlsbad, CA). DNA sequencing was
performed to check correct insertion of the cDNA using an ABI3100 automatic
sequencer (Applied Biosystems, Courtaboeuf, France). Adenoviruses ex-
pressing in tandem green ﬂuorescent protein (GFP) and ATGL or HSL were
constructed, puriﬁed, and titrated (Vector Biolabs, Philadelphia, PA). An ad-
enovirus containing the GFP gene only was used as a control. Myotubes were
infected with the control (GFP), ATGL, and HSL adenoviruses at day 4 of
differentiation and remained exposed to the virus for 24 h in serum-free
DMEM containing 150 mmol/L of oleate complexed to BSA (ratio 4:1). Oleate
was preferred to palmitate for lipid loading of the cells to favor TAG synthesis
and to avoid the intrinsic lipotoxic effect of palmitate (20,21). No adenovirus-
induced cellular toxicity was observed as determined by chemiluminescent
quantiﬁcation of adenylate kinase activity (ToxiLight, Lonza Group Ltd., Basel,
Switzerland). For insulin signaling experiments, infected myotubes were in-
cubated for 20 min in DMEM low glucose with or without 100 nmol/L of insulin
(Sigma-Aldrich, Lyon, France).
Determination of glycogen synthesis. Cells were preincubated with a
glucose- and serum-free a-minimum essential medium for 90 min and then
exposed to DMEM supplemented with D[U-
14C]glucose (1 mCi/mL; PerkinElmer,
Boston, MA) in the presence or absence of 100 nmol/L insulin for 3 h. After
incubation, glycogen synthesis was determined as described previously (22).
Pulse-chase studies of lipid metabolism. Cells were pulsed overnight (18 h)
with a combination of [1-
14C]oleate (1 mCi/mL; PerkinElmer) and unlabeled
oleate (100 mmol/L ﬁnal concentration) to prelabel the endogenous TAG pool.
After incubation, myotubes were chased for 3 h in nutrient-deﬁcient DMEM
containing 0.1 mmol/L glucose and 0.5% FFA-free BSA. At the end of in-
cubation, total lipids were extracted in chloroform/methanol (2v/1v) and
separated by thin-layer chromatography as previously described (23). Incor-
poration rates were normalized to total protein content measured in each well.
Western blot analysis. Muscle tissues and cell extracts were homogenized in
a buffer containing 50 mmol/L HEPES, pH 7.4, 2 mmol/L EDTA, 150 mmol/L
NaCl, 30 mmol/L NaPO4, 10 mmol/L NaF, 1% Triton X-100, 10 mL/mL protease
inhibitor (Sigma-Aldrich), 10 mL/mL phosphatase I inhibitor (Sigma-Aldrich),
10 mL/mL phosphatase II inhibitor (Sigma-Aldrich), and 1.5 mg/mL benzami-
dine HCl. Tissue homogenates were centrifuged for 25 min at 15,000g,a n d
supernatants were stored at 280°C. Solubilized proteins from muscle tissue
and myotubes were run on a 4–12% SDS-PAGE (Bio-Rad, Hercules, CA),
transferred onto nitrocellulose membrane (Hybond ECL, GE Healthcare,
Buckingamshire, U.K.), and incubated with the primary antibodies (ATGL, Cell
Signaling Technology Inc., Beverly, MA; Perilipin-A, Abcam Inc., Cambridge,
MA). The HSL antibody was as previously described (24). Antibodies for in-
sulin signaling p-Ser473–Akt, Akt, p-Ser1101–IRS-1, p-Tyr612–IRS-1, IRS-1, and
p-Ser660–HSL were all from Cell Signaling Technology Inc. Subsequently, im-
munoreactive proteins were determined by enhanced chemiluminescence re-
agent (GE Healthcare, Waukesha, WI) and visualized by exposure to Hyperﬁlm
ECL (GE Healthcare). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(Cell Signaling Technology Inc.) served as an internal control.
Subjects. Nine young lean, nine young obese, and eight obese subjects with
type 2 diabetes were recruited in the study (Table 1). The subjects with type 2
diabetes were diet-controlled or were taking metformin (n=6) and insulin
(n=2), and were otherwise healthy with an average HbA1c of 7.0 6 0.78%.
None of them were taking thiazolidinediones. The protocol was approved by
the institutional review board of the Pennington Biomedical Research Center,
and all volunteers gave written informed consent. After participants com-
pleted the screening visit, fat mass was measured on a Hologic Dual Energy
X-Ray Absorptiometer (QDR 2000, Hologic Inc., Bedford, MA). The partic-
ipants were asked to refrain from vigorous physical activity for 48 h before
presenting to the Pennington inpatient clinic and ate a weight-maintaining diet
consisting of 35% fat, 16% protein, and 49% carbohydrate 2 days before the
clamp and the muscle biopsy. Samples of vastus lateralis weighing 60–100 mg
were obtained by muscle biopsy using the Bergstrom technique, blotted,
cleaned, and snap-frozen in liquid nitrogen (25).
Hyperinsulinemic euglycemic clamp. Insulin sensitivity was measured by
clamp (26). After an overnight fast, insulin (80 mU $ m
22 $ min
21) and 20%
glucose (to maintain plasma glucose at 90 mg/dL) were administered for 2 h.
Glucose and insulin were measured in three independent blood plasma sam-
ples 5 min apart at baseline and again at steady-state after approximately 2 h.
Glucose disposal rate was adjusted for kilograms of fat-free mass.
Lipase activity assays. TAG hydrolase (TAGH) and DAG hydrolase (DAGH)
activitieswere measuredoncell extractsas previously described(24,27).Brieﬂy,
1(3)-mono[
3H]oleyl-2-O-mono-oleylglycerol (MOME) and [9, 10-
3H(N)]triolein
were emulsiﬁed with phospholipids by sonication. MOME is a DAG analog that
allows for the measurement of DAGH activity because it is not a substrate for
monoacylglycerol lipase. [9, 10-
3H(N)]triolein was used to determine spe-
ciﬁcally TAGH activity, and [
3H]MOME was used to determine speciﬁcally
DAGH activity.
TAG and DAG determination by gas chromatography-mass spectrometry.
Total lipids were extracted from frozen muscle tissue samples and from
myotubes harvested in water containing 0.25 mL 0.1% SDS. Lipids were
extracted using the method of Folch et al. (28). The extracts were ﬁltered, and
lipids were recovered in the chloroform phase. TAG and DAG were isolated
using thin-layer chromatography on Silica Gel 60 A plates developed in pe-
troleum ether, ethyl ether, and acetic acid (80:20:1), and visualized by rhoda-
mine 6G. The TAG and DAG band was scraped from the plate and methylated
using BF3/methanol as described by Morrison and Smith (29). The methylated
FFAs were extracted with hexane and analyzed by gas chromatography us-
ing an HP 5890 gas chromatograph equipped with ﬂame ionization detectors,
an HP 3365 Chemstation, and a capillary column (SP2380, 0.25 mm 3 30 m,
0.25 µm ﬁlm; Supelco, Bellefonte, PA). Helium was used as a carrier gas. The
oven temperature was programmed from 160 to 230°C at 4°C/min. FFA
methyl esters were identiﬁed by comparing the retention times with those of
known standards. Inclusion of the internal standards, 20:1 (trieicosenoin)
and 17:0 (diheptadecanoin), permits quantitation of the amount of TAG and
DAG in the sample.
Ceramide determination by electrospray ionization tandem mass
spectrometry. Ceramide was quantiﬁed by electrospray ionization tandem
mass spectrometry as previously described (30). Brieﬂy, lipid extracts were
prepared by the method of Bligh and Dyer (31) in the presence of nonnaturally
occurring Cer 14:0, Cer 17:0. Samples were analyzed by direct ﬂow injection on
a Quattro Ultima triple-quadrupole mass spectrometer (Micromass, Manchester,
U.K.) using an HTS PAL autosampler (CTC Analytics AG, Zwingen, Switzerland)
and an Agilent 1100 binary pump (Agilent Technologies GmbH, Waldbronn,
Germany) with a solvent mixture of methanol containing 10 mmol/L ammo-
nium acetate and chloroform (3:1, v/v). A ﬂow gradient was performed starting
with a ﬂow of 55 µL/min for 6 s followed by 30 µL/min for 1.0 min and an
increase to 250 µL/min for another 12 s. Ceramide was analyzed using a frag-
ment of m/z 264 with N-heptadecanoyl-sphingosine as internal standard. Both
ions [M+H]
+ and [M+H-H2O]
+ were used, and quantiﬁcation was achieved by
calibration lines generated by addition of Cer 16:0, 18:0, 20:0, 24:1, 24:0 to
tissue and cell samples, respectively. Correction of isotopic overlap of ceramide
species and data analysis were performed by self-programmed Excel (Microsoft
Corp., Redmond, WA) macros according to the principles described previously
(32).
Statistical analyses. All statistical analyses were performed using GraphPad
Prism 5.0 for Windows (GraphPad Software Inc., San Diego, CA). One-way
ANOVA followed by Bonferroni post hoc tests and paired, two-tailed Student
t tests were performed to determine differences between groups and treat-
ments. Two-way ANOVA and Bonferroni post hoc tests were used when ap-
propriate. Normal distribution of the data was tested using the Shapiro-Wilk
normality test. The relationships between muscle ATGL protein and clinical
variables were analyzed using Spearman rank correlations. All values in Figs. 1
to 7 and Table 1 are presented as mean 6 SEM. Statistical signiﬁcance was set
at P , 0.05.
RESULTS
Relationship between muscle ATGL and insulin
sensitivity. We ﬁrst investigated the relationship between
skeletal muscle ATGL protein content and insulin sensitivity
TABLE 1
Clinical characteristics of the subjects
Lean (9) Obese (9)
Type 2
diabetes (8)
Sex (male/female) 6/3 5/4 6/2
Age (years) 23.8 6 0.8 23.7 6 0.8 53.8 6 3.8
b,e
Body weight (kg) 66.4 6 3.6 94.5 6 3.4
c 102.4 6 4.2
c
BMI (kg/m
2) 22.5 6 0.5 32.9 6 0.5
c 35.4 6 1.7
c
Body fat (%) 20.4 6 2.8 31.1 6 1.6
a 37.5 6 2.9
b
GDR (mg/min/kg FFM) 9.3 6 0.8 7.0 6 0.6
a 5.3 6 0.6
c
Fasting glucose
(mmol/L) 4.67 6 0.12 4.81 6 0.13
a 7.51 6 0.76
b,d
Fasting insulin (mU/L) 8.4 6 1.2 13.2 6 1.1
a 13.7 6 2.9
a
Data are mean 6 SEM. FFM, fat-free mass; GDR, glucose disposal
rate.
aP , 0.05,
bP , 0.01,
cP , 0.001 vs. lean;
dP , 0.01,
eP , 0.001
vs. obese.
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obese, and type 2 diabetic subjects. The characteristics of
the subjects are described in Table 1. As expected, obese
and type 2 diabetic subjects had lower insulin sensitivity
and higher body fat, fasting glucose, and fasting insulin
compared with lean subjects. Muscle ATGL protein content
was signiﬁcantly elevated in type 2 diabetic subjects when
compared with lean and obese subjects (0.50 6 0.04, 0.45 6
0.05, and 0.65 6 0.07 arbitrary units [AU] for lean, obese,
and type 2 diabetic subjects, respectively) (Fig. 1A and E).
We also conﬁrm a reduced HSL Ser660 phosphorylation
(0.43 6 0.08 vs. 0.27 6 0.05 AU, 236%) (Fig. 1C and E)a n d
HSL protein content (0.47 6 0.09 vs. 0.25 6 0.07 AU, 248%)
(Fig. 1B and E) in skeletal muscle of obese compared with
lean subjects. HSL Ser660 phosphorylation (0.68 6 0.21 vs.
0.43 6 0.08 AU) and total HSL (1.05 6 0.43 vs. 0.47 6 0.09
AU) tended to increase in type 2 diabetic subjects com-
pared with lean subjects. The ratio of phosphorylated HSL
Ser660 to total HSL was not signiﬁcantly changed between
groups (Fig. 1D). We noted a signiﬁcant inverse relationship
between muscle ATGL protein content and whole-body in-
sulin sensitivity measured by euglycemic hyperinsulinemic
clamp across individuals (Fig. 1F). Similarly, muscle ATGL
protein was positively correlated with fasting glucose levels
(r =0 . 5 6 ,P , 0.005). Perilipin-A protein was not detectable
in any of the muscle samples excluding signiﬁcant con-
tamination by inﬁltrated adipocytes (data not shown).
Adenovirus-mediated ATGL overexpression. We used
an adenovirus gene delivery method to overexpress ATGL
in our cell culture model. ATGL protein expression was
induced by ;3.4 6 0.2-fold (Fig. 2A). ATGL overexpression
increased TAGH activity twofold (Fig. 2B), but did not
change DAGH activity as expected (Fig. 2C). We checked
that the ATGL enzyme was operative in intact cells by di-
rectly measuring the rate of incorporation of radiolabeled
oleate into different lipid pools. We could show that ATGL
overexpression reduced the rate of incorporation of [1-
14C]
oleate into TAG (Fig. 2D), whereas the rate of incorporation
was increased into DAG (Fig. 2E) and intracellular FFA
(Fig. 2F).
Elevated ATGL expression promotes DAG and cer-
amide accumulation. We found that total TAG content was
reduced in myotubes overexpressing ATGL (0.60 6 0.07-
fold, P , 0.01) (Fig. 3A). Conversely, consistent with an
FIG. 1. Skeletal muscle lipase protein expression in lean, obese, and type 2 diabetic subjects. Quantitative bar graph of ATGL protein (A), HSL
protein (B), HSL Ser660 phosphorylation (C), and the ratio HSL Ser660 phosphorylation to total HSL (D) in vastus lateralis samples of lean,
obese, and type 2 diabetic subjects. E: Representative blots of lipases and the loading control GAPDH. F: Relationship between vastus lateralis
ATGL protein expression and glucose disposal rate measured by euglycemic hyperinsulinemic clamp across individuals. White square, lean; black
square, obese; open circle, type 2 diabetes. *P < 0.05 compared with obese; §P = 0.08 compared with lean.
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creased in myotubes overexpressing ATGL (1.5 6 0.1-fold)
(Fig. 3B). Ceramide content was also increased in myotubes
overexpressing ATGL (2.9 6 0.7-fold), possibly as a conse-
quence of increased intracellular FFA ﬂux and de novo
ceramide synthesis (Fig. 3C).
Elevated ATGL expression impairs insulin signaling
and action. We ﬁrst showed that glycogen synthesis under
insulin stimulation was impaired by 30% (P , 0.05) in
myotubes overexpressing ATGL (Fig. 4A). Insulin-stimulated
glycogen synthesis was signiﬁc a n t l yr e d u c e di nm y o t u b e s
overexpressing ATGL (0.72 6 0.07-fold, P = 0.01). We further
showed that ATGL overexpression increased Ser1101–IRS-1
phosphorylation by twofold at baseline and under insulin
stimulation (P , 0.001) (Fig. 4B and D). IRS-1 phosphory-
lation at Ser1101 inhibits IRS-1 tyrosine phosphorylation and
function and is a primary target for PKC (13), suggesting
a possible link between ATGL and PKC activation. Down-
stream insulin activation of Akt on the residue Ser473 was
also impaired (change insulin minus baseline 231%, P ,
0.05) during ATGL overexpression. Ser473 Akt phosphory-
lation was increased at baseline (P , 0.05) and reduced
under insulin stimulation in ATGL-overexpressing myotubes,
whereas total Akt protein content was not different across
treatments (Fig. 4C and D).
ATGL-mediated insulin resistance involves DAG and
PKC activation. Because several isoforms of novel PKC
have been linked to insulin resistance (33), we used a
broad range nonselective PKC inhibitor in our experi-
ments. Calphostin C treatment greatly enhanced insulin-
stimulated Akt activation in ATGL overexpressing myotubes
(+163%, P , 0.01 compared with GFP with calphostin C)
FIG. 2. ATGL overexpression increases TAG hydrolysis in myotubes. A: Quantitative bar graph of ATGL protein during adenovirus-mediated ATGL
overexpression vs. GFP control (n =4 ) .Insets are showing representative blots of two independent experiments. TAG hydrolase activity (B) and
DAG hydrolase activity (C) were measured in control myotubes (GFP) and myotubes overexpressing ATGL (n = 4). Pulse-chase studies using
[1-
14C]oleate were performed to determine the kinetics of the different lipid pools in response to ATGL overexpression. The rate of incorporation
of radiolabeled oleate into (D) TAG, (E) DAG, and (F) FFA was determined in control myotubes (GFP) and myotubes overexpressing ATGL. *P <
0.05; **P < 0.01 vs. GFP (n =4 ) .
FIG. 3. Elevated ATGL expression promotes DAG and ceramide accumulation. Determination of (A) TAG, (B) DAG, and (C) ceramide content in
control myotubes (GFP) and myotubes overexpressing ATGL. *P < 0.05 (n =5 ) .
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rescued insulin-stimulated glycogen synthesis to control
GFP levels in myotubes overexpressing ATGL (Fig. 5C).
PKC inhibition by the nonselective inhibitor calphostin C
(1 mmol/L) was sufﬁcient to fully rescue ATGL-mediated
insulin resistance. ATGL-mediated inhibition of glycogen
synthesis and Akt phosphorylation was not prevented
by the de novo ceramide synthesis inhibitor myriocin
(10 mmol/L) (Supplementary Fig. 1).
HSL overexpression is sufﬁcient to rescue ATGL-
mediated insulin resistance. We tested the hypothesis
that restoring a proper cellular lipolytic balance could re-
verse ATGL-mediated insulin resistance. To do so, we
concomitantly overexpressed ATGL and HSL in differ-
entiated myotubes and examined insulin signaling and
action. HSL overexpression by itself did not produce lipo-
toxicity and insulin resistance (Supplementary Fig. 2). The
concomitant overexpression of HSL and ATGL increased
both HSL (3.4 6 0.8-fold, P , 0.05) and ATGL (3.2 6 0.6-fold,
P , 0.05) protein content, TAGH activity (4.4 6 2.0-fold, P ,
0.01), and DAGH activity (5.1 6 1.8-fold, P , 0.01). When
coexpressed with ATGL, HSL was sufﬁcient to completely
rescue ATGL-mediated insulin resistance. This was evi-
denced by a full restoration of insulin-mediated Akt acti-
vation (Fig. 6A and B) and glycogen synthesis (Fig. 6C)t o
GFP control levels in myotubes coexpressing ATGL and
HSL compared with ATGL alone.
Selective HSL inhibition impairs insulin signaling. We
next examined the effect of HSL-selective inhibition by the
BAY compound on DAG levels and insulin action. BAY has
been shown to be a highly selective HSL inhibitor in pre-
vious studies (24). We observed a moderate increase in
total DAG levels (+29%, P = 0.068) in myotubes treated for
24 h with 1 mmol/L of BAY (Fig. 7A). BAY treatment did
not increase ceramide content (0.57 6 0.07 vs. 0.57 6 0.06
nmol/mg for control and BAY, respectively). In the same
treatment condition, BAY reduced Tyr612–IRS-1 phosphor-
ylation on insulin treatment (230%, P , 0.05) (Fig. 7B
and C) and insulin-mediated Akt phosphorylation (228%,
P =0 . 0 3 )( F i g .7 B and D). We did not observe additive
effects of ATGL overexpression combined with HSL in-
hibition compared with ATGL overexpression alone on
insulin-stimulated Akt Ser473 phosphorylation (Supple-
mentary Fig. 3).
DISCUSSION
Ectopic fat deposition in non-adipose tissues such as
skeletal muscle is a common feature of insulin resistance
in obesity and type 2 diabetes (3–5). The mechanisms
underlying IMTG accumulation and elevated lipotoxicity in
insulin-resistant states are not yet fully understood. We
show for the ﬁrst time a novel mechanism by which an
altered lipolytic balance in skeletal muscle might contrib-
ute to lipotoxicity and insulin resistance in humans. An
imbalance of ATGL relative to HSL promotes DAG accu-
mulation and induces insulin resistance at least in part
through a DAG/PKC pathway.
We ﬁrst showed that ATGL protein expression in vastus
lateralis samples obtained from a wide range of subjects
was negatively associated with whole-body insulin sensi-
tivity measured by euglycemic hyperinsulinemic clamp. It
is interesting to note that the glucose disposal rate during
this clamp is mostly accounted by skeletal muscle and thus
mostly reﬂects skeletal muscle insulin sensitivity in lean
subjects. Higher doses of insulin are required to fully
suppress hepatic glucose production in obese and type 2
diabetic subjects as previously shown (34). Thus, the re-
lationship between muscle ATGL and insulin sensitivity is
stronger in lean subjects than in obese and type 2 diabetic
FIG. 4. Elevated ATGL expression disrupts insulin signaling and action. A: Glycogen synthesis was measured in the absence (open bars) or
presence (black bars) of 100 nmol/L insulin in control myotubes (GFP) and myotubes overexpressing ATGL. *P < 0.05, **P < 0.01 vs. basal; #P < 0.05
vs. GFP insulin (n = 8 per group). B: Quantitative bar graph of basal Ser1101 IRS-1 phosphorylation (n = 4). ***P < 0.001 vs. GFP. C: Quantita-
tive bar graph of Ser473 Akt phosphorylation (n = 11). *P < 0.05, ***P < 0.001 vs. basal; #P < 0.05 vs. Ad-GFP. D: Representative blots of Ser1101
pIRS-1, total IRS-1, Ser473 pAkt, total Akt, and the loading control GAPDH in the presence (+) or absence (2) of 100 nmol/L of insulin in control
myotubes (GFP) and myotubes overexpressing ATGL.
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obese type 2 diabetic subjects displayed increased muscle
ATGL protein content. This ﬁnding is slightly in contrast
with recent data showing an increased skeletal muscle
ATGL protein expression in nondiabetic obese versus age-
matched lean individuals (35). The discrepancy could be
explained by an effect of aging because the type 2 diabetic
subjects were older than the lean and obese subjects in our
study. Thus, age-related changes in skeletal muscle lipases
with respect to insulin sensitivity should be further ex-
plored. Elevated muscle ATGL protein in obese type 2 di-
abetic subjects is in agreement with a higher muscle DAG
FIG. 5. ATGL-mediated insulin resistance involves PKC activation. A: Representative blots of Ser473 pAkt, total Akt, and GAPDH in the presence
(+) or absence (2) of insulin and the nonselective PKC inhibitor calphostin C (1 mmol/L) in control myotubes (GFP) and myotubes overexpressing
ATGL. B: Quantitative bar graph of insulin-stimulated Ser473 Akt phosphorylation (n = 3); insulin-stimulated Akt phosphorylation was calculated
as the D between basal and insulin stimulation in each condition. *P < 0.05 vs. GFP; ##P < 0.01 vs. GFP calphostin C. C: Insulin-stimulated
glycogen synthesis in myotubes expressing GFP and ATGL in the absence (control) or presence of calphostin C. Glycogen synthesis was expressed
as the D change between glycogen synthesis under insulin stimulation and glycogen synthesis at baseline. *P < 0.05 vs. GFP (n =4 ) .
FIG. 6. Rescue of ATGL-mediated insulin resistance by HSL. A: Representative blots of Ser473 pAkt, total Akt, and GAPDH in the presence (+) or
absence (2) of insulin in control myotubes (GFP) and myotubes overexpressing ATGL alone (Ad-ATGL) or in combination with HSL (Ad-ATGL+
Ad-HSL). B: Quantitative bar graph of insulin-stimulated Ser473 Akt phosphorylation (n = 4); insulin-stimulated Akt phosphorylation was cal-
culated as the D between basal and insulin stimulation in each condition. *P < 0.05 vs. GFP. C: Insulin-stimulated glycogen synthesis was measured
in control myotubes (GFP) and myotubes overexpressing ATGL alone (Ad-ATGL) or in combination with HSL (Ad-ATGL+Ad-HSL). *P < 0.05 vs.
GFP (n =6 ) .
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next evaluated the causal relationship between elevated
ATGL expression and insulin resistance in primary culture
of skeletal muscle cells.
We overexpressed ATGL in human primary myotubes
using an adenovirus and assessed the consequences on
lipids and insulin action. Elevated expression of ATGL
reduced TAG content and simultaneously increased DAG
and ceramide content. Ceramides are potentially produced
de novo through the action of serine palmitoyl-transferase
I as previously shown (8). ATGL-mediated lipotoxicity
was paralleled by impairment in insulin-stimulated glyco-
gen synthesis and insulin signaling possibly due to PKC-
mediated Ser1101-IRS-1 phosphorylation and downstream
inhibition of Akt Ser473 phosphorylation. Of note, increased
ATGL expression induced baseline Akt Ser473 phosphor-
ylation independently of insulin. This suggests that ATGL
may activate potential regulators of Ser473 Akt, such as
mTORC2, by yet unknown mechanisms (37). Future studies
will be required to dissect the precise mechanism by which
ATGL elicits baseline Akt activation. IRS-1 phosphoryla-
tion at Ser1101 is primarily mediated by PKCu and induces
general inhibition of IRS-1 function (13). Together, our
data show that ATGL mediates insulin resistance at least in
part through DAG and PKC activation. Itani et al. (38,39)
have previously shown that membrane-associated PKCb
and u protein content and activity increased the skeletal
muscle of obese versus lean and obese diabetic versus
nondiabetic matched control subjects, respectively. Even
if the exact nature of DAG stereoisomers produced by the
action of ATGL is currently unknown, the data support
an important role for DAG in mediating skeletal muscle
insulin resistance in this model. This observation is con-
sistent with other studies showing a critical role of DAG
in mediating insulin resistance in liver (40) and skeletal
muscle (10–12) in response to high-fat diets and lipid infu-
sions. Our results are also consistent with a study by Bell
et al. (41) suggesting that AML12 liver cells lacking the lipid
coat protein adipophilin and tail-interacting protein of
47 kDa develop insulin resistance with increased recruitment
of ATGL to lipid droplets.
Of interest, ATGL-mediated insulin resistance was fully
rescued by HSL after restoring a proper cellular lipolytic
balance. Overexpression of HSL by itself did not cause
lipotoxicity and insulin resistance contrary to ATGL. HSL
displays a high DAG substrate speciﬁcity and is considered
the major DAG hydrolase in several tissues (42). This
supports the concept that the functional balance between
ATGL and HSL may inﬂuence intracellular DAG concen-
trations and insulin action in skeletal muscle. Altogether,
these data highlight a potential protective role of DAG
hydrolases against intramyocellular lipotoxicity by their
ability to rapidly hydrolyze DAG. The importance of DAG
turnover in insulin resistance is also illustrated by the
protective role of DGAT1 against intramyocellular lipo-
toxicity and fat-induced insulin resistance by increasing
lipid partitioning into IMTG (43,44). Along these lines, re-
duced DAG kinase-d activity, which converts DAG into
phosphatidic acid, might also contribute to skeletal muscle
insulin resistance by increasing total DAG level (45).
Consistent with recent studies that reported a robust
reduction in skeletal muscle HSL protein expression in
insulin-resistant obese subjects (35,46), our study con-
ﬁrmed that both HSL Ser660 phosphorylation and HSL
protein content were reduced in skeletal muscle of obese
compared with lean subjects. The trend for increased HSL
protein content in skeletal muscle of patients with type 2
diabetes could be explained by the hyperglycemic milieu
because glucose was shown to induce HSL transcription in
adipocytes (47). To study the impact of reduced HSL
FIG. 7. Selective HSL inhibition disrupts insulin signaling. A: Total DAGs were measured in control myotubes and myotubes treated for 24 h with
1 mmol/L of the selective HSL inhibitor BAY (n =6 ) .B: Representative blots of Tyr1162 pIR, total IRalpha, Ser473 pAkt, total Akt, and GAPDH in
the presence (+) or absence (2) of insulin in control myotubes and myotubes treated with BAY. Quantitative bar graphs of (C)T y r 6 1 2 - I R S - 1
phosphorylation (n =4 )a n d( D) Ser473 Akt phosphorylation (n = 4) in control myotubes and myotubes treated with the BAY compound. **P < 0.01;
***P < 0.001 vs. basal; #P < 0.05 vs. control insulin.
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the consequences of inhibiting HSL activity on lipid pools
and insulin sensitivity in myotubes. HSL activity is regu-
lated by phosphorylation on serine residues in response
to muscle contraction and catecholamines in vivo (48).
Jocken et al. (46) found that reduced HSL phosphorylation
at Ser563, Ser565, and Ser659 was entirely due to lower
HSL protein content and associated with reduced resting
glycerol release from the forearm muscle of obese sub-
jects. We report that selective inhibition of HSL increases
speciﬁcally total DAG levels and consequently disrupts
insulin receptor signaling and action. This observation is
somehow consistent with data on HSL knockout mice that
are insulin-resistant at the level of the skeletal and cardiac
muscles when fed a chow diet (49,50) and accumulate
DAG in their muscles (16). Further studies will be required
to unravel the precise mechanism by which reduced HSL
expression/activity induces insulin resistance in skeletal
muscle.
In conclusion, the current study highlights a new mech-
anism by which an altered lipolytic balance between ATGL
and HSL induces DAG and insulin resistance in skeletal
muscle. The molecular mechanism involves at least in part
DAG-mediated PKC activation. Future studies should ex-
plore the cause-effect relationship between altered lipase
expression and insulin resistance in vivo in animal models
with targeted modulations of lipase expression in skeletal
muscle. Targeting skeletal muscle lipases might be of po-
tential therapeutic interest for improving insulin resistance
in obesity and type 2 diabetes.
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